Showing results (101-110 of 179) with videos related to
Sort By:
Pageof 18
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|December 3, 2003
Chemoprevention for Barrett's esophagus trial. Design and outcome measuresE I Heath, M I Canto, T-T Wu, et al.European Journal of Cancer (Oxford, England : 1990)|January 12, 2024
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305Athanassios Argiris, Yael Flamand, Panayiotis Savvides, et al.Seminars in Radiation Oncology|April 21, 1999
Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatinW Flood, D J Lee, A Trotti, et al.International Journal of Radiation Oncology, Biology, Physics|May 10, 2003
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancerLawrence Kleinberg, Jonathan P S Knisely, Richard Heitmiller, et al.The Laryngoscope|November 5, 2014
Short- and long-term outcomes of laryngeal cancer care in the elderlyChristine G Gourin, Heather M Starmer, Robert J Herbert, et al.British Journal of Cancer|March 8, 2007
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacyA Jimeno, P Kulesza, J Wheelhouse, et al.International Journal of Radiation Oncology, Biology, Physics|March 15, 2016
Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial DesignLawrence R Kleinberg, Paul J Catalano, Arlene A Forastiere, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399Anthony J Cmelak, Sigui Li, Meredith A Goldwasser, et al.Head & Neck|September 23, 1998
Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy?J S Cooper, T F Pajak, A Forastiere, et al.Head & Neck|July 14, 2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology GroupJill Gilbert, Ju Whei Lee, Athanassios Argiris, et al.Pageof 18